Cargando…
Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant Escherichia coli
Fluoroquinolones (FQs) belong to the class of quinolone drugs that are used to treat Urinary tract infections (UTIs) through inhibition of E. coli DNA gyrase. Resistance to FQs poses a serious problem in the treatment against resistant strains of E. coli which are associated with Ser83 to Leu and As...
Autores principales: | Balasubramaniyan, Sakthivel, Irfan, Navabshan, Umamaheswari, Appavoo, Puratchikody, Ayarivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081776/ https://www.ncbi.nlm.nih.gov/pubmed/35540291 http://dx.doi.org/10.1039/c8ra01854e |
Ejemplares similares
-
3-D structural interactions and quantitative structural toxicity studies of tyrosine derivatives intended for safe potent inflammation treatment
por: Puratchikody, Ayarivan, et al.
Publicado: (2016) -
gyrA Mutations in Fluoroquinolone-resistant Clostridium difficile PCR-027
por: Drudy, Denise, et al.
Publicado: (2007) -
Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients
por: Kabir, Saba, et al.
Publicado: (2020) -
Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis
por: Anand, RS, et al.
Publicado: (2011) -
New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations
por: Malik, Seidu, et al.
Publicado: (2012)